

### 90 Vantage

### **Undertakings for Collective Investment in Transferable Securities (UCITS)**

April 2025

#### Month in Review

Equity markets were weaker in April. World equities fell 4% in euro terms. Europe was the strongest performer - followed by Japan and Asia Pacific ex Japan. US and Small cap were the weakest performers. Utilities, Consumer staples and Industrials were the strongest sectors. Energy, Health care and REITs were the weakest.

The announcement by Trump in early April of significant new global tariffs impacted markets. Markets were also unsettled by Trumps criticism of Fed chairman Powell and this also had a negative effect on the US dollar which weakened against the euro. This impacted returns in euro terms from US markets in April. In Emerging Markets, China fell sharply as it was impacted by concerns over a potential trade war with the US as tariffs were ramped up significantly during the month.

Wolters Kluwer, iShares STOXX Europe 600 Insurance UCITS ETF and First Trust Nasdaq Clean Edge Smart Grid Infrastructure UCITS ETF were the best performers. Xtrackers MSCI World Energy UCITS ETF, Nike and Norfolk Southern were the weakest performers.


#### Historical Performance | Net of Fees

	1 MTH	3 MTH	YTD	1 YR	3 YR p.a	5 YR p.a
Vantage 90 Fund	-3.9%	-13.8%	-10.5%	3.1%	6.2%	10.6%
Benchmark	-4.0%	-11.6%	-9.0%	5.4%	7.6%	12.2%
	2024	2023	2022	2021	2020	Since Launch
Vantage 90 Fund	23.5%	18.8%	-16.8%	29.0%	4.4%	75.5%
Benchmark	25.0%	17.9%	-12.7%	27.4%	6.4%	94.6%

Source: Goodbody

The benchmark is the FTSE All World Index

## Regional Allocation as at 30 April 2025



North America	72%
Europe ex UK	15%
Asia Pacific	7%
UK	4%
Emerging markets	2%
Source: Goodbody	

# Sector Breakdown as at 30 April 2025

Information Technology	25%
Financials	18%
Industrials	15%
Health Care	14%
<b>Consumer Discretionary</b>	11%
<b>Communication Services</b>	6%
Materials	3%
Energy	3%
Consumer Staples	3%
Utilities	1%
Real Estate	1%
Source: Goodbody	

Warning: If you invest in this fund you may lose some or all of the money you invest.

Warning: Past performance is not a reliable guide to future performance.

#### **Fund Objective**

The investment objective of the Fund is to deliver strong real appreciation in the value of capital over the medium term. The Fund seeks to achieve this investment objective by investing in equity assets.

#### **Key information**

Fund launch date	13 December 2018
Fund type	UCITS
Base currency	€
Pricing/Dealing	Daily
ISIN	IE00BGRCCT35
Month end NAV (€)	17.5
Investment manager	ment fee 1.25%



#### Contact us today

Goodbody, 9-12 Dawson Street, Dublin 2

- **T** +353 1 641 9105
- **E** karl.s.goggin@goodbody.ie
- **W** www.goodbody.ie

### Top 10 equity holdings as at 30 April 2025

Apple	5%
Microsoft	4%
Nvidia	4%
Amazon	3%
Visa	2%
Wolters Kluwer	2%
S&P Global	2%
Safran	2%
CRH	2%
Tesla	2%

Source: Goodbody

Warning: The value of your investment may go down as well as up.

Warning: This fund may be affected by changes in currency exchange rates.

Warning: Dividend Income is not guaranteed and may rise or fall in value.

The Fund is a sub-fund of Goodbody Funds ICAV, which is an undertaking for Collective Investment in Transferable Securities (UCITS) with limited liability between sub-funds. Investors should read the Prospective Supplement and Key Information document for the Fund, as well as the Information Memorandum prior to making a decision to invest, and for full information on the Fund including fees, risks and conflicts of interest.

This document is a marketing communication. This document is not in itself a prospectus, an invitation to invest or advice. Please refer to the UCITS prospectus and KID before making any final investment decisions.

### Goodbody

#### www.goodbody.ie

Dublin	London	Cork	Galway	Wealth Management
9-12 Dawson Street,	70 St. Mary Axe,	City Quarter,	Unit 4, Dockgate,	Investment Banking
Dublin 2	London, EC3A 8BE	Lapps Quay, Cork	Dock Road, Galway	Asset Management
<b>T</b> +353 1 667 0400	<b>T</b> +44 203 841 6220	<b>T</b> +353 21 427 9266	<b>T</b> +353 91 569 744	Capital Partners

Prepared by Goodbody Investment Team Produced April 2025

#### Disclaimer

This publication has been approved by Goodbody Stockbrokers UC. The information has been taken from sources we believe to be reliable, we do not guarantee their accuracy or completeness and any such information may be incomplete or condensed. All opinions and estimates constitute best judgement at the time of publication and are subject to change without notice. The information, tools and material presented in this document are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities.

This document is not to be relied upon in substitution for the exercise of independent judgement. Nothing in this publication constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you. Goodbody Stockbrokers UC does not advise on the tax consequences of investments and you are advised to contact an independent tax advisor. Please note in particular that the basis and levels of taxation may change without notice. Private customers having access to this document, should not act upon it in anyway but should consult with their independent professional advisors. The price, value and income of certain investments may rise or may be subject to sudden and large falls in value. You may not recover the total amount originally invested.

Past performance should not be taken as an indication or guarantee of future performance; neither should simulated performance. The value of securities may be subject to exchange rate fluctuations that may have a positive or adverse effect on the price or income of such securities. Goodbody Stockbrokers UC and its associated companies and/ or its officers may from time to time perform banking or Corporate Finance services including underwriting, managing or advising on a public offering for, or solicit business from any company recommended in this document. They may own or have positions in any securities mentioned herein and may from time to time deal in such securities. Goodbody Stockbrokers UC is a registered market maker in the majority of companies listed on the Irish Stock Exchange plc, trading as Euronext Dublin. Protection of investors under the UK Financial Services and Markets Act 2000 (as amended) may not apply. Irish Investor Compensation arrangements will apply. For US Persons Only: This publication is only intended for use in the United States by Major Institutional Investors. A Major Institutional Investor is defined under Rule 15a-6 of the Securities Exchange Act 1934 as amended and interpreted by the SEC from time-to-time as having total assets in its own account or under management in excess of \$100 million.

All material presented in this publication, unless specifically indicated otherwise is copyright to Goodbody Stockbrokers UC. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of Goodbody Stockbrokers UC.

Registered Office: 9-12 Dawson Street, Dublin 2, Ireland. T: +353 1 667 0400. Registered in Ireland No. 54223.

Goodbody Stockbrokers UC acts as broker to: AlB Group, Cairn Homes, CRH, Datalex, FD Technologies, Grafton Group, Greencore, Hostelworld Group, ICG, Kingspan, LungLife AI, Molten Ventures, Origin Enterprises, Playtech, Rank Group and Ryanair.

Goodbody Stockbrokers UC, trading as Goodbody, is regulated by the Central Bank of Ireland and Goodbody Stockbrokers UC is authorised and regulated in the United Kingdom by the Financial Conduct Authority. Goodbody is a member of Euronext Dublin and the London Stock Exchange. Goodbody is a member of the group of companies headed by AIB Group plc. Goodbody Securities Inc. is regulated by the SEC and a member firm of FINRA and SIPC. 001354\_0525